Practice-Changing Results Seen in Phase III Relapsed/Refractory AML Trial
Results of the phase III ADMIRAL trial, which tested the FLT3 inhibitor gilteritinib in patients with relapsed/refractory acute myeloid leukemia, were presented at the AACR Annual Meeting.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Source Type: news